Montelukast As An Adjunct To Treatment of Chronic Rhinosinusitis With Polyposis: A Prospective Randomized Controlled Trial.

In a prospective, randomized controlled trial, forty consecutive adult patients with bilateral nasal polyps were randomized into two groups. Twenty subjects in Group A were treated with oral prednisolone for 14 days and budenoside nasal spray for 8 weeks while the twenty subjects in Group B received a similar treatment with additional oral montelukast for 8 weeks. Subjects completed a modified nasal ICSD symptom score at the start of treatment and at 8 and 12 weeks after beginning the treatment. Symptom scores improved in both the groups after treatment. Subjects in Group B reported a statistically significant improvement in sense of smell (p = 0.0002), sneezing (p = 0.008) and overall score (p = 0.0006) at 8 weeks than controls. Four weeks after the completion of treatment, a statistically significant improvement was seen in the sense of smell (p = 0.0006), headache (p = 0.03) and overall score (p = 0.003) in patients in Group B when compared to Group A. Montelukast therapy may have clinical benefit as an adjunct to oral and inhaled steroid in chronic nasal polyposis.